Exane BNP Paribas upgraded Aperam to Outperform from Neutral with a EUR 34 price target. The company’s free cash flow will bounce back in fiscal 2024 and shares trade at a compelling valuation, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on APEMY:
- Aperam price target lowered to EUR 30 from EUR 31 at Morgan Stanley
- APEMY Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Aperam price target raised to EUR 20 from EUR 19.50 at JPMorgan
- Aperam price target lowered to EUR 25 from EUR 28 at Barclays
- Aperam price target lowered to EUR 19.50 from EUR 22.70 at JPMorgan
